Targeting AMD patient treatment burden

September 15, 2020

Intravitreal gene therapy continues to be well tolerated; shows robust efficacy

OCTA: Why the jury may still be out

September 11, 2020

Though OCTA has become indispensable for managing macular degeneration and diabetic retinopathy, Robert L. Stamper, MD, explains why the technology must become more sophisticated and evolved before it reaches its full potential for glaucoma specialists.

Regenxbio: Dosing of first patient in Phase 2 AAVIATE trial for wet AMD

September 09, 2020

Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020